KPV

KPV (Lys-Pro-Val) is a naturally occurring tripeptide corresponding to the C-terminal fragment (residues 11-13) of alpha-melanocyte-stimulating hormone (α-MSH). Despite being only three amino acids, KPV retains the potent anti-inflammatory activity of the full 13-amino acid α-MSH peptide while lacking its melanogenic (tanning) and hormonal effects. This dissociation of anti-inflammatory activity from melanocortin receptor-mediated effects makes KPV an attractive candidate for inflammatory conditions where pigmentation changes would be an unwanted side effect.

KPV has been studied primarily in the context of intestinal inflammation and skin disorders, with preclinical data showing efficacy in colitis models and dermatitis. Its small molecular size (342 Da) offers practical advantages — oral bioavailability, skin penetration, and low manufacturing cost relative to larger peptides. The peptide is part of a broader research effort to identify the minimal active fragments of endogenous anti-inflammatory peptides for therapeutic development.

KPV's anti-inflammatory mechanism is unusual for a peptide — it acts intracellularly rather than through surface receptor binding. While full-length α-MSH exerts anti-inflammatory effects through MC1R and MC3R signaling, KPV is too small to effectively engage melanocortin receptors. Instead, KPV is transported into cells where it directly interacts with the p65 (RelA) subunit of NF-κB, the master transcription factor for inflammatory gene expression. KPV inhibits p65 nuclear translocation and DNA binding, suppressing transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12), adhesion molecules, and inducible enzymes (COX-2, iNOS).

This intracellular mechanism operates at remarkably low concentrations — picomolar range (10^-12 M) — suggesting high-affinity binding to its intracellular target. KPV also inhibits activation of IκB kinase (IKK), the upstream kinase complex that phosphorylates IκB to release NF-κB. The dual inhibition at both the IKK and p65 levels produces robust suppression of inflammatory signaling. In intestinal epithelial cells, KPV has been shown to be internalized via the PepT1 transporter, which may explain its oral bioactivity in colitis models.